杭州華浙生物醫(yī)藥有限公司 成立于2022年12月，公司前身為南京華興醫(yī)藥科技有限公司中間體事業(yè)部，2022年獨(dú)立后自主經(jīng)營發(fā)展并獲得進(jìn)出口權(quán)。

現(xiàn)主營業(yè)務(wù)覆蓋醫(yī)藥、獸藥中間體，原料藥，保健品等產(chǎn)品研發(fā)、生產(chǎn)及國內(nèi)外銷售等，2024年銷售額突破1億元人民幣。公司技術(shù)儲備充足，已商業(yè)化銷售成熟中間體208個(gè)，每年開發(fā)中間體-API項(xiàng)目10-20個(gè)。

公司在南京、臺州設(shè)有研發(fā)和中試實(shí)驗(yàn)室；在福建明溪、黑龍江雞西、哈爾濱蘭西、湖北荊州等地都有合作生產(chǎn)基地。工廠已通過美國FDA、歐盟EDQM、中國NMPA等cGMP現(xiàn)場檢查。

Hangzhou Huazhe Biopharmaceuticals Co., Ltd. was established in December 2022. It was formerly the Pharmaceutical intermediate department of Nanjing Huaxing Pharmaceutical Technology Co., Ltd. and became independent in 2022 with the right to import and export.

The current main business covers the R&D, production and domestic and foreign sales of products such as pharmaceutical and veterinary intermediates, APIs and healthcare products.In 2024, the company's sales exceeded 100 million RMB.

With abundant technical reserves, it has commercialized 208 mature intermediates and develops 10- 20 intermediate- API projects annually.